Potential SARS-CoV-2 antiviral to be tested in human lung cells
A synthetic antiviral named R327 has shown promise in initial tests against SARS-CoV-2 and is now advancing to the next stage of in vitro studies.
List view / Grid view
A synthetic antiviral named R327 has shown promise in initial tests against SARS-CoV-2 and is now advancing to the next stage of in vitro studies.
Researchers have shown that a protein named aquaporin can disrupt optical development, leading to cataract formation.
A new assay has been developed to screen for small molecule inhibitors of the Rh5 protein, which is essential for malaria parasite survival.
A new modelling method could be used as a surveillance tool to monitor emerging infectious SARS-CoV-2 variants, scientists say.
Combining two genomic methodologies, researchers have shown that pancreatic exocrine cells are implicated in type 1 diabetes.
A synthetically made glycopeptide biologic has shown promise as a treatment for obesity-related diseases in mice.
Scientists have created an antiviral therapy using lipid nanoparticles that deliver siRNA to the lungs to treat COVID-19 in mice.
Using electrochemical detection and redox labels, researchers have created a new, faster method to sequence DNA.
Having identified the histone demethylase KDM5A as a multiple myeloma target, researchers developed a KDM5 inhibitor to treat the cancer.
A new conjugate vaccine has shown promise at protecting mice against the effects of cytokines associated with asthma.
Researchers have measured the gene expression of healthy and cancerous single cells from breast tissue, creating an 'RNA atlas'.
Microfluidic screening technologies have been used to discover a promising antibody candidate against SARS-CoV-2 and the South African variant.
A new pre-clinical mouse model could enable the study of HIV infection and the testing of cell therapies against the virus.
Researchers have shown in fruit flies that lipid droplets could prevent the kidney damage that leads to chronic kidney disease.
A team has shown that the NapA protein, associated with Lyme disease, attracts inflammatory molecules in the body.